The estimated Net Worth of Divestiture Trust Biotest is at least $94.4 Million dollars as of 6 June 2019. Divestiture Biotest owns over 5,813,954 units of Adma Biologics Inc stock worth over $72,638,258 and over the last 7 years Divestiture sold ADMA stock worth over $21,802,328.
Divestiture has made over 2 trades of the Adma Biologics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Divestiture sold 5,813,954 units of ADMA stock worth $21,802,328 on 6 June 2019.
The largest trade Divestiture's ever made was selling 8,591,160 units of Adma Biologics Inc stock on 14 May 2018 worth over $145,276,516. On average, Divestiture trades about 7,202,557 units every 194 days since 2018. As of 6 June 2019 Divestiture still owns at least 4,295,580 units of Adma Biologics Inc stock.
You can see the complete history of Divestiture Biotest stock trades at the bottom of the page.
Divestiture's mailing address filed with the SEC is 402 Norfolk St, Cambridge, MA 02139, USA.
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ..., and Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Inc executives and other stock owners filed with the SEC include: